𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study

✍ Scribed by Ryoichi Honda; Akihisa Fujita; Yuhji Inoue; Mitsuo Asakawa; Akira Suzuki

Publisher
Springer
Year
1990
Tongue
English
Weight
315 KB
Volume
26
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Urokinase combination chemotherapy in sm
Urokinase combination chemotherapy in small cell lung cancer. A phase II study
✍ F. A. Calvo; O. F. Hidalgo; F. Gonzalez; J. Rebollo; S. Martin Algarra; D. Ortiz 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 770 KB

## Background and methods: Fifty-one patients with small cell lung cancer (sclc) were treated with alternating urokinase (uk)-cyclophosphamide-doxorubicin (adriamycin, adria laboratories, columbus, oh)-vincristine and cisplatin-etoposide-vincristine. uk was given as a loading dose of 3000 microgram

A phase I-II study of docetaxel-ifosfami
A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer
✍ Christos Kosmas; Nicolas B. Tsavaris; Thomas Makatsoris; Adimchi Onyenadum; Mari 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 96 KB 👁 1 views

## Abstract In an attempt to develop more effective chemotherapy regimens in advanced nonsmall cell lung cancer (NSCLC), we evaluated docetaxel‐ifosfamide‐cisplatin (DIP) based on our previous experience with paclitaxel‐ifosfamide‐cisplatin. Patients with advanced NSCLC (stages III‐IV), WHO‐PS≤2, n